MDGL
MADRIGAL PHARMACEUTICALS, INC.
Nasdaq: MDGL · West Conshohocken, PA · Healthcare
$476.89+9.61 (+2.06%)Closed
Market Cap$10.99B
Cash$227.0Mmost recent
Runway4 mo$167.4M Q burn
P/E (TTM)—EPS $-12.85
52-Wk Range$277.64 – $602.83
Avg Volume345.8K3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$476.89+87.1%
Pipeline
Drug candidates sponsored by MADRIGAL PHARMACEUTICALS · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | Placebo | Non-Alcoholic Fatty Liver Disease+1 more | Completed | 2023-01-06past | 3 | |
| Phase 3 | Resmetirom | NASH+3 more | Recruiting | 2026-12 | 3 | |
| Phase 3 | MGL-3196 | NASH - Nonalcoholic Steatohepatitis+4 more | Active, not recruiting | 2028-01 | 6 | |
| Phase 2 | MGL-3196 (resmetirom) | Heterozygous Familial Hypercholesterolemia | Completed | 2018-01-15past | 1 | |
| Phase 1 | Simvastatin | Healthy | Completed | 2015-10past | 1 | |
| Phase 1 | Atorvastatin | Healthy | Completed | 2016-05past | 1 | |
| Phase 1 | MGL-3196 Tablet | Healthy | Completed | 2018-02-17past | 1 | |
| Phase 1 | 100 mg Resmetirom Tablet | Renal Impairment | Completed | 2024-09-16past | 1 | |
| N/A | Rezdiffra | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Recruiting | 2030-04-08 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for MDGL. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.